Cargando…
Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients
Organ dysfunction or overt failure is a commonplace event in the critically ill affecting up to 70% of patients during their stay in the ICU. The outcome depends on the resolution of impaired organ function, while a domino-like deterioration of organs other than the primarily affected ones paves the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511746/ https://www.ncbi.nlm.nih.gov/pubmed/36163253 http://dx.doi.org/10.1186/s13054-022-04163-1 |
_version_ | 1784797706190848000 |
---|---|
author | Perez Ruiz de Garibay, Aritz Kortgen, Andreas Leonhardt, Julia Zipprich, Alexander Bauer, Michael |
author_facet | Perez Ruiz de Garibay, Aritz Kortgen, Andreas Leonhardt, Julia Zipprich, Alexander Bauer, Michael |
author_sort | Perez Ruiz de Garibay, Aritz |
collection | PubMed |
description | Organ dysfunction or overt failure is a commonplace event in the critically ill affecting up to 70% of patients during their stay in the ICU. The outcome depends on the resolution of impaired organ function, while a domino-like deterioration of organs other than the primarily affected ones paves the way for increased mortality. “Acute Liver Failure” was defined in the 1970s as a rare and potentially reversible severe liver injury in the absence of prior liver disease with hepatic encephalopathy occurring within 8 weeks. Dysfunction of the liver in general reflects a critical event in “Multiple Organ Dysfunction Syndrome” due to immunologic, regulatory and metabolic functions of liver parenchymal and non-parenchymal cells. Dysregulation of the inflammatory response, persistent microcirculatory (hypoxic) impairment or drug-induced liver injury are leading problems that result in “secondary liver failure,” i.e., acquired liver injury without underlying liver disease or deterioration of preexisting (chronic) liver disease (“Acute-on-Chronic Liver Failure”). Conventional laboratory markers, such as transaminases or bilirubin, are limited to provide insight into the complex facets of metabolic and immunologic liver dysfunction. Furthermore, inhomogeneous definitions of these entities lead to widely ranging estimates of incidence. In the present work, we review the different definitions to improve the understanding of liver dysfunction as a perpetrator (and therapeutic target) of multiple organ dysfunction syndrome in critical care. GRAPHIC ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-9511746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95117462022-09-27 Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients Perez Ruiz de Garibay, Aritz Kortgen, Andreas Leonhardt, Julia Zipprich, Alexander Bauer, Michael Crit Care Review Organ dysfunction or overt failure is a commonplace event in the critically ill affecting up to 70% of patients during their stay in the ICU. The outcome depends on the resolution of impaired organ function, while a domino-like deterioration of organs other than the primarily affected ones paves the way for increased mortality. “Acute Liver Failure” was defined in the 1970s as a rare and potentially reversible severe liver injury in the absence of prior liver disease with hepatic encephalopathy occurring within 8 weeks. Dysfunction of the liver in general reflects a critical event in “Multiple Organ Dysfunction Syndrome” due to immunologic, regulatory and metabolic functions of liver parenchymal and non-parenchymal cells. Dysregulation of the inflammatory response, persistent microcirculatory (hypoxic) impairment or drug-induced liver injury are leading problems that result in “secondary liver failure,” i.e., acquired liver injury without underlying liver disease or deterioration of preexisting (chronic) liver disease (“Acute-on-Chronic Liver Failure”). Conventional laboratory markers, such as transaminases or bilirubin, are limited to provide insight into the complex facets of metabolic and immunologic liver dysfunction. Furthermore, inhomogeneous definitions of these entities lead to widely ranging estimates of incidence. In the present work, we review the different definitions to improve the understanding of liver dysfunction as a perpetrator (and therapeutic target) of multiple organ dysfunction syndrome in critical care. GRAPHIC ABSTRACT: [Image: see text] BioMed Central 2022-09-26 /pmc/articles/PMC9511746/ /pubmed/36163253 http://dx.doi.org/10.1186/s13054-022-04163-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Perez Ruiz de Garibay, Aritz Kortgen, Andreas Leonhardt, Julia Zipprich, Alexander Bauer, Michael Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients |
title | Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients |
title_full | Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients |
title_fullStr | Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients |
title_full_unstemmed | Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients |
title_short | Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients |
title_sort | critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511746/ https://www.ncbi.nlm.nih.gov/pubmed/36163253 http://dx.doi.org/10.1186/s13054-022-04163-1 |
work_keys_str_mv | AT perezruizdegaribayaritz criticalcarehepatologydefinitionsincidenceprognosisandroleofliverfailureincriticallyillpatients AT kortgenandreas criticalcarehepatologydefinitionsincidenceprognosisandroleofliverfailureincriticallyillpatients AT leonhardtjulia criticalcarehepatologydefinitionsincidenceprognosisandroleofliverfailureincriticallyillpatients AT zipprichalexander criticalcarehepatologydefinitionsincidenceprognosisandroleofliverfailureincriticallyillpatients AT bauermichael criticalcarehepatologydefinitionsincidenceprognosisandroleofliverfailureincriticallyillpatients |